Call for Abstract

12th Global
Pharmacovigilance & Clinical Trials Summit, will be organized around the theme “Comprehend Multiple Facets of Pharmacovigilance, Drug Safety and Clinical Trials”

Global Pharmacovigilance 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Global Pharmacovigilance 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Significance of pharmacovigilance
  • Track 1-2Pharmacovigilance and healthcare system
  • Track 1-3Pharmacovigilance legislation
  • Track 1-4Role of pharma industries in the improvement of pharmacovigilance system
  • Track 1-5Detection and evaluation of drug safety signals through manual and medical devices reporting
  • Track 1-6Ecopharmacovigilance (EPV)
  • Track 1-7pharmacoenvironmentology
  • Track 1-8Pharmacovigilance in herbal medicines
  • Track 1-9Methods of pharmacovigilance
  • Track 1-10Post market product surveillance
  • Track 2-1Role of pharmacovigilance and pharmacoepidemiology in risk management
  • Track 2-2Good reporting practices
  • Track 2-3Signal investigation via observational studies
  • Track 2-4Interpreting safety signals
  • Track 2-5Randomized clinical trials
  • Track 3-1Classification of various adverse drug reactions
  • Track 3-2Mechanism of adverse drug reactions
  • Track 3-3Assessing and reporting adverse drug reactions
  • Track 3-4Expected and un-expected drug reactions and its reporting
  • Track 3-5Post marketing reports on adverse effects
  • Track 4-1Drug Safety Updates
  • Track 4-2Drug Safety Solutions
  • Track 4-3Drug Safety Training
  • Track 4-4Drug Safety Surveilance
  • Track 4-5Drug Safety Services & Softwares
  • Track 4-6Drug Safety Reporting & Monitoring
  • Track 4-7Pharmacoepidemiology
  • Track 5-1Advances in pharmacokinetic interactions
  • Track 5-2Advances in pharmacodynamic interactions
  • Track 5-3Drug and substance abuse
  • Track 5-4Data monitoring for trials with an adaptive design
  • Track 5-5Drug-drug interactions
  • Track 5-6Systems Pharmacology
  • Track 6-1Phases of clinical trials
  • Track 6-2Innovations in patient and community engagement in clinical trials
  • Track 6-3Heterogeneity of treatment effect in randomized clinical trials
  • Track 6-4Treating different ailments by clinical trials
  • Track 6-5Pre-clinical research leading to clinical trials
  • Track 7-1Pre-clinical research/trail
  • Track 7-2Clinical Trial Management
  • Track 7-3Clinical research phase studies
  • Track 7-4In Vitro and In Vivo studies
  • Track 7-5Bioequivalence Protocol
  • Track 7-6Trial design: formulation development
  • Track 7-7Efficacy and Effectiveness of the trail
  • Track 7-8Role of Biomarkers
  • Track 8-1Discovery and Preclinical Testing Phases
  • Track 8-2Pre-Clinical Testing
  • Track 8-3Clinical Study Designs
  • Track 8-4Bioassay and its types
  • Track 8-5Data collection and quality control
  • Track 8-6Alternative trials design and models
  • Track 8-7Multi center trials and monitoring
  • Track 8-8Regulatory authorities and ethics committee
  • Track 8-9Advanced Information technology in clinical trials and promoting companies
  • Track 9-1Innovative approaches to patient recruitment
  • Track 9-2Innovative partnering in clinical research
  • Track 9-3Design for predictive bio marker validation
  • Track 9-4Randomized placebo- controlled trials
  • Track 10-1Stem Cell & Oncology
  • Track 10-2Diabetes & Gastroenterology¬†
  • Track 10-3Sexually Transmitted Diseases
  • Track 10-4Cardiovascular
  • Track 10-5Cancer
  • Track 10-6Vaccines
  • Track 10-7Zika Virus
  • Track 10-8Applications of biomarkers in clinical trials
  • Track 11-1Data types and data processing techniques
  • Track 11-2Advanced products in data management
  • Track 11-3Bayesian data analysis
  • Track 11-4Sequential treatment factors for controlled trials
  • Track 11-5ICH guidelines for clinical research and its statistics
  • Track 11-6Data mining concepts and techniques
  • Track 11-7Stastical analysis of past pharmacovigilance and adverse drug reactions reports
  • Track 12-1Case reports dealing with the use of novel technologies
  • Track 12-2Case reports in oncology, diabetes and cardiovascular diseases
  • Track 12-3Dermatology, gastroenterology, Nephrology, pulmonology and urology case reports
  • Track 12-4Case reports in neurology, ophthalmology, obstetrics and gynecology
  • Track 12-5Case reports on drugs used in psychological disorders
  • Track 12-6Case reports on drugs used in respiratory disorders
  • Track 12-7Case reports on drugs used in pregnancy and lactation
  • Track 13-1Information technology in pharmacovigilance and promoting companies
  • Track 13-2Review of softwares used in pharmacovigilance and clinical trials
  • Track 13-3Risk communication: Interface between pharmacovigilance, sales and marketing
  • Track 13-4Monitoring unlicensed, off labels and orphan drugs
  • Track 13-5Risk Management of Pre-Clinical and Clinical Research
  • Track 13-6Genetic Epidemiology in Risk Management
  • Track 13-7Pharmacovigilance in Risk Management
  • Track 13-8Pharmacoepidemiology in Clinical Research
  • Track 13-9Information technology in pharmacoepidemiology and clinical trials
  • Track 14-1Regulatory Guidelines
  • Track 14-2USFDA
  • Track 14-3MHRA
  • Track 14-4Regulations in Pharmacovigilance
  • Track 14-5Medical writing Pharmacovigilance
  • Track 15-1Quality Assurance
  • Track 15-2Quality Control
  • Track 15-3Challenges in compounding and dispensing practice
  • Track 15-4Dosage regimen, drug toxicity and drug safety measures
  • Track 15-5Industrial pharmaceutics
  • Track 15-6Supply chain management
  • Track 15-7Waste management
  • Track 15-8Product management